3 April 2003 Treatment as prevention: why? Gus Cairns Editor, HIV Treatment Update.

Slides:

Advertisements

Similar presentations

9th Advanced HIV Course Aix-en-Provence 2011 Role of ARV as Prevention Martin Fisher Brighton and Sussex University Hospitals, UK.

Advertisements

STIs in Victoria who why prevention Rebecca Guy Centre for Epidemiology and Population Health Research, The Macfarlane Burnet Institute for Medical Research.

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.

Slide 1 of 42 IAS–USA Treatment as Prevention: Evaluating the Impact of HAART Expansion The British Columbia (BC) Experience AU EDITED FINAL:

STIGMA AND DISCRIMINATION REDUCTION AS AN ESSENTIAL PART OF COMBINATION PREVENTION Stefan Baral, MD MPH FRCPC Center for Public Health and Human Rights,

HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.

From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.

Treatment as prevention: cannot succeed without increased testing AND PRIMARY PREVENTION example from the United Kingdom? Dr Valerie Delpech Head of HIV.

Transmission risk between couples: the “science” Martin Fisher Brighton and Sussex University Hospitals NHS Trust Gus Cairns National AIDS Manual.

BHIVA Service Commissioning Survey – 2014 Tuesday 4 November 2014.

Offering ARV Treatment to All HIV-infected Persons in San Francisco Grant Colfax, MD Director of HIV Prevention and Research San Francisco Department of.

Treatment as prevention (TASP) for HIV and HCV: The evidence and modelling Peter Vickerman.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective.

Potential role of PEP, PrEP and ART for HIV Prevention among Men who have Sex with Men Frits van Griensven, PhD, MPH Division of HIV/AIDS Prevention US.

The CDC Prevention Grant Funding Opportunity Announcement (FOA) and OA’s Response Overview and Discussion September 21, 2011 California Department of Public.

How well are we doing in preventing HIV and how can we do better?

Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

2 New HIV diagnoses and number of persons accessing HIV care in the United Kingdom: 2014.

The potential and challenges of ARV-based HIV prevention: An overview

Can we reach UNAIDS targets and will this lead to the elimination of HIV in the UK? Dr Valerie Delpech Head of national HIV surveillance.

Undetectable = Uninfectious ? Treatment as Prevention.

Community viral load and newly reported HIV infections in Switzerland Matthias Egger Professor of Epidemiology & Public Health Institute of Social and.

Changes in population-level HIV RNA distribution one year after implementation of key components of an HIV ‘test and treat’ strategy in rural Uganda Vivek.

What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.

Slide 1 of 42 IAS–USA AU EDITED FINAL: Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director,

ILGA, Community involvement in prevention trials Gus Cairns Policy Working Group, European AIDS Treatment Group: Editor, HIV Treatment.

1 st International Treatment as Prevention (TasP) Workshop Overview British Columbia Centre for Excellence in HIV/AIDS Julio Montaner MD, DSc(hon), FRCPC,

NURSETRI, Nursing role in HIV care : an overview Jane Bruton Clinical Research Nurse.

Immigration Removal Centres and HIV Clinical Care Jane Anderson Homerton University Hospital NHS Foundation Trust.

AIDS 2012 Where are we, and where are we going? Mitchell Warren Executive Director, AVAC August 15, 2012.

Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.

Where are we in HIV reduction among gay, bisexual, and other men who have sex with men? Barry D Adam University Professor Senior Scientist & Director of.

Treatment as Prevention and Treatment 2.0 Update UN Forum on AIDS, 24 June 2011 Nicole Seguy, Zhang Lan, WHO.

Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.

Martin Fisher Foundation: 14 September Remembering Martin Fisher Simon Collins, HIV i-Base Who should get tested? How and why should.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.

High-impact interventions. Number of people living with HIV who were not receiving antiretroviral therapy, 2014 and 2015 Source: UNAIDS estimates, 2014.

ARV-Based Prevention: Perspective from Epidemiology & Modelling Tim Hallett Imperial College London.

MINNESOTA’S HIV TREATMENT CASCADE April, Introduction.

Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Washington Seattle, Washington A Shot in the Arm for HIV Prevention? Opportunities and.

PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

Grinsztejn B, et al, Lancet Infect Dis, March 4 th 2014 PRIMARY COMBINED M&M OUTCOME FIRST AIDS DEFINING EVENT FIRST TB EVENT DEATH.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System Predictors for high viraemia among the treatment naïve population.

HIV Prevention: A Winnable Battle Centers for Disease Control and Prevention.

THE BIOMEDICAL AND THE SOCIAL IN HIV PREVENTION Barry D Adam University Professor Senior Scientist and Director of Prevention Research.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER HIV Prevention in Clinical Care Settings Jeanne Marrazzo, MD, MPH Professor, Division of Allergy and Infectious.

BRADFORD BRIGGS & NIKE JACKSON. BRADFORD BRIGGS Prevention Toolbox.

HIV PRE-EXPOSURE PROPHYLAXIS (PREP) YUMA HEALTH DISTRICT 5/23/16 ALYSSA GUIDO, MPH PROGRAM DIRECTOR, ARIZONA AETC ARIZONA AIDS EDUCATION AND TRAINING CENTER.

Expanded PrEP implementation across Australia Expanded implementation of PrEP across Australia 1.

Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.

Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.

Status Neutral: The New Normal for HIV

What are the Opportunities and Challenges?

East Bay HIV Update Conference

California PrIDE Prep for PrEP November 15, 2016

HIV-1 PLASMA VIRAL LOAD IN TREATMENT NAÏVE HIV-1 PATIENTS

دانشگاه علوم پزشکی بوشهر برنامه ملی مبارزه با بیماریهای واگیر

differentiated care – Innovating for Impact: Civil Society View

The Politics of PrEP The French Experience

Advancing PrEP in family planning clinics: what will it take?

An Update from CROI and the Changing Landscape of HIV in NZ

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

Analytic framework illustrating exposure to preventive measures that reduce the risk of transmission between HIV-serodiscordant sex partners. Analytic.

Presentation transcript:

3 April 2003 Treatment as prevention: why? Gus Cairns Editor, HIV Treatment Update

24 November 2010 NAT Treatment as Prevention HIV diagnoses

24 November 2010 NAT Treatment as Prevention Condom use in UK gay men

24 November 2010 NAT Treatment as Prevention Treatment as prevention: evidence? Montaner, Lancet 376: 532 – 539, 2010

24 November 2010 NAT Treatment as Prevention BC study again

24 November 2010 NAT Treatment as Prevention San Francisco Das-Douglas, CROI 2010, abstract #33

24 November 2010 NAT Treatment as Prevention What would it take in San Francisco? In San Francisco 85.5% are diagnosed of whom 78% are linked to care of whom 90% are on ARVs of whom 72% are undetectable = 43.2% of people with HIV in San Francisco have an undetectable viral load (due to treatment)

24 November 2010 NAT Treatment as Prevention Imperial College mathematical model Getting 80% of people with CD4 under 350 on treatment would be enough to reduce transmission by >90% if: Lower-risk pops tested every 2-3 years High-risk pops test every 6m Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 24: , 2010

24 November 2010 NAT Treatment as Prevention A wild card: PrEP IPrEx study, results 2 days ago 44% efficacy on 51% adherence Potentially 70-90% efficacy: cf condoms Practical? Affordable? Applicable? Dangerous? We may need to start thinking of ARVs-as-prevention for HIV-negative as well as HIV- positive people ?Pilot study of ARV treatment for high-risk HIV-negative testers nested within TasP project? Grant RM et al. Preexposure chemoprophylaxis for HIV prevention in men. New Engl Jour Med 23 November 2010.